Companies · Other Health Care

VivoSense, Inc.

NEWPORT COAST · Other Health Care

Diligence memoA one-page analyst read on VivoSense, Inc. — recommendation, valuation, rhythm, risks.
$27.0M
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 14%
Sector rank · raised
Series B
Latest stage · inferred · Fri Mar 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

VivoSense, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.19× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

VivoSense, Inc. is one of 5376 Other Health Care companies tracked from NEWPORT COAST. By capital raised it ranks in the upper tier (ahead of 87% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2022-03-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2019-05-23 Raised $2.0M (real) Modeled valuation $50M (est)$2.0M$50MSeed2019Series B · 2022-03-04 Raised $25M (real) Modeled valuation $332M (est)$25M$332MSeries B2022Series A · 2022-03-04 Raised $10M (real) Modeled valuation $111M (est)$10M$111MSeries A2022+$25M+$10MCumulative $37M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.0M · 2019
Series B$25.0M · 2022no Series A on file
Bridge · Series B-stage$10.0M · 2022smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$332.3M
Base estimate est.
$58.8M
Conservative case
$928.3M
Upside case
$138.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $49.6M · 2019-05-232019Series B · modeled $332.3M · 2022-03-04Series A · modeled $110.7M · 2022-03-042022
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
4.3 yr
Elapsed time used
4.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
17 mo
Avg between rounds
$9.7M/yr
Capital velocity
7.1 yr
On record since
2019
First round
3
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 11× above median
This company$27.0M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.6× of median
This company$10.0M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 15× above median
This company$332.3M
Sector median$22.1M

Raised more than 87% of sector peers (real $). Modeled value above 91% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #8 of 91.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Code Biotherapeutics, Inc. · Series B Raised $47.5M · modeled $465.5M (est)Candesant Biomedical, Inc. · Series B Raised $44.5M · modeled $455.0M (est)Artis Holdings, LLC · Series B Raised $40.0M · modeled $383.2M (est)GIO Blood Ltd · Series B Raised $27.3M · modeled $375.2M (est)Clarapath, Inc. · Series B Raised $40.2M · modeled $348.1M (est)Diality Inc · Series B Raised $42.9M · modeled $337.4M (est)VA Pro 7 SNF Operations Holdings LLC · Series B Raised $32.0M · modeled $333.0M (est)Tidal Wave GPO, LLC · Series B Raised $34.8M · modeled $324.3M (est)Peachy Corp. · Series B Raised $25.1M · modeled $309.6M (est)Smile Source Holdings, L.P. · Series B Raised $32.2M · modeled $308.7M (est)ASC San Rafael LLC · Series B Raised $28.3M · modeled $294.9M (est)VivoSense, Inc. (this company) Raised $27.0M · modeled $332.3M (est)VivoSense, Inc.
CompanyStageRaised · realValue · estvs peer med.
Code Biotherapeutics, Inc.Series B$47.5M$465.5M3.06×
Candesant Biomedical, Inc.Series B$44.5M$455.0M2.99×
Artis Holdings, LLCSeries B$40.0M$383.2M2.52×
GIO Blood LtdSeries B$27.3M$375.2M2.47×
Clarapath, Inc.Series B$40.2M$348.1M2.29×
Diality IncSeries B$42.9M$337.4M2.22×
VA Pro 7 SNF Operations Holdings LLCSeries B$32.0M$333.0M2.19×
VivoSense, Inc. this companySeries B$27.0M$332.3M2.19×
Tidal Wave GPO, LLCSeries B$34.8M$324.3M2.13×
Peachy Corp.Series B$25.1M$309.6M2.04×
Smile Source Holdings, L.P.Series B$32.2M$308.7M2.03×
ASC San Rafael LLCSeries B$28.3M$294.9M1.94×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.0M2019-05-23$10.0M$49.6M90%
Series B$25.0M2022-03-04$138.9M$332.3M90%
Series A$10.0M2022-03-04$45.5M$110.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.0M2019-05-23
    • First recorded raise — entered as Seed.
    • 1 investor on this round.
  2. Series B$25.0M2022-03-04
    • Raised again after 33 mo — slower than the ~14 mo sector norm.
    • Round 12.5× larger than the prior — scaling up.
    • 2 investors on this round.
  3. Series A$10.0M2022-03-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 2 investors on this round.
Intelligence
2023 ~Q3
Modeled next raise · ~17mo cadence
$10.0M
Modeled next size est.range $10.0M$16.0M
0.4×
Last step-up
$9.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Chris Jonathan Garabedian2022-03
Colin Bower2022-03
David Hankey2019-05
David Jonathan Hankey2022-03
Douglas Jonathan McAllister2022-03
Douglas McAllister2019-05
Dudley Jonathan Tabakin2022-03
Dudley Tabakin2019-05
Lance Jonathan Myers2022-03
Lance Myers2019-05
Marc Jonathan Cikes2022-03
Peter Foster2019-05
Peter Jonathan Foster2022-03
Ralf Hempfling2019-05
Ralf Jonathan Hempfling2022-03
Registry & provenance

VivoSense, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1778463
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Aspire Bariatrics, LLCOther Health CareSeries B$27.0M$359.1Msame sector · same stage
GIO Blood LtdOther Health CareSeries B$27.3M$375.2Msame sector · same stage
DocAsap, Inc.Other Health CareSeries B$27.4M$398.8Msame sector · same stage
VoCare, Inc.Other Health CareSeries B$27.6M$443.1Msame sector · same stage
Edgewood OpCo, LLCOther Health CareSeries B$28.0M$177.4Msame sector · same stage
Eyenuk, Inc.Other Health CareSeries B$28.3M$262.6Msame sector · same stage
Virobay IncOther Health CareSeries B$28.3M$398.8Msame sector · same stage
ASC San Rafael LLCOther Health CareSeries B$28.3M$294.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Vivos IncOther Health CarePre-Seed$22.3M92%
BioIntelliSense, Inc.Other Health CareSeries C$328.7M89%
Audio Bionics International Inc.Other Health CarePre-Seed$30.8M85%
Vivo Management, Inc.OtherSeries A$22.1M85%
Cardionomic, Inc.Other Health CareSeries B$76.2M85%
Beta Bionics, IncOther Health CareSeries C$1.0B84%
Healthsense IncHealthtechSeries A$65.5M84%
UE LifeSciences Inc.Other Health CarePre-Seed$7.5M84%
Frequently asked
How much funding has VivoSense, Inc. raised?
VivoSense, Inc. has raised approximately $27.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is VivoSense, Inc.'s estimated valuation?
Provath's modeled valuation for VivoSense, Inc. is approximately $332.3M (modeled range $58.8M–$928.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is VivoSense, Inc. at?
VivoSense, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Mar 04.
What does VivoSense, Inc. do and where is it based?
VivoSense, Inc. operates in the Other Health Care sector, based in NEWPORT COAST.
Explore related

See where VivoSense, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at VivoSense, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.